Risk of fracture following androgen receptor pathway inhibitors in men with advanced prostate cancer - PubMed
4 days ago
- #Prostate Cancer
- #Fracture Risk
- #Bone Health
- This study examines fracture risk in advanced prostate cancer patients treated with androgen receptor pathway inhibitors (ARPIs).
- The research analyzed 10,463 patients (6,037 on AAP, 4,426 on ENZA) from SEER-Medicare files (2013-2020).
- 3-year fracture risk exceeded 25% in patients without prior fractures and 50% in those with recent fractures.
- Prior fracture history increased fracture risk by 2.84-fold (aHR: 2.84, 95% CI 2.58-3.12).
- Osteoporosis and high comorbidity scores were linked to 15% and 11% higher fracture risks, respectively.
- Bone health agents (BHAs) reduced fracture risk by 23% (aHR: 0.77, 95% CI 0.70-0.83).
- Despite BHA use, fracture risk remained high (>44%) in patients with prior fractures, indicating limited benefit in poor bone quality.
- Early identification and intervention for high-risk patients are crucial to mitigate fracture risks.